Board of directors (11)
Directors with a Section 16 filing in the last 13 months. “Since” is the first filing as a director; SEC data sets start in 2016.
Executive officers (5)
Company facts
- Chair
- —
- In S&P 500 since
- Jan 2002
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC industry
- Laboratory Analytical Instruments
- SEC filings
- EDGAR
Connections to other S&P 500 companies
Current directors and officers who also hold a role at another S&P 500 company.
Major holders (5% or more)
Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.
No 5% holder filings parsed yet for this company.
Insider trades
Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 6, 2026 | Christopher A. Kuebler Director | Sale | 3,626 | $397.94 | $1.4M |
| Mar 16, 2026 | Wei Jiang Director | Buy | 500 | $289.46 | $145K |
| Mar 6, 2026 | Richard H. Fearon Director | Buy | 1,000 | $306.34 | $306K |
| May 28, 2024 | Richard H. Fearon Director | Buy | 1,000 | $332.90 | $333K |
| May 15, 2024 | Christopher A. Kuebler Director | Sale | 4,000 | $361.64 | $1.4M |
| Mar 13, 2024 | Linda Baddour Director | Sale | 500 | $355.54 | $178K |
| Aug 4, 2023 | Christopher A. Kuebler Director | Sale | 4,000 | $291.48 | $1.2M |
| Feb 28, 2023 | Mark Vergnano Director | Buy | 3,185 | $313.32 | $998K |
| Nov 30, 2022 | Edward Conard Director | Sale | 1,059 | $334.70 | $354K |
| May 19, 2022 | Christopher A. Kuebler Director | Sale | 4,000 | $328.78 | $1.3M |
| Dec 2, 2021 | Edward Conard Director | Sale | 4,000 | $336.01 | $1.3M |
| Aug 18, 2021 | Christopher A. Kuebler Director | Sale | 3,000 | $405.62 | $1.2M |
| Aug 16, 2021 | Linda Baddour Director | Sale | 1,260 | $408.99 | $515K |
| Aug 13, 2021 | Michael J. Berendt Director | Sale | 806 | $403.12 | $325K |
| Aug 12, 2021 | Michael J. Berendt Director | Sale | 4,000 | $398.43 | $1.6M |
| Aug 5, 2021 | Thomas P. Salice Director | Sale | 3,500 | $395.00 | $1.4M |
| Aug 5, 2021 | Thomas P. Salice Director | Sale | 5,000 | $395.00 | $2.0M |
| May 24, 2021 | Michael J. Berendt Director | Sale | 1,161 | $318.24 | $369K |
| May 13, 2021 | Linda Baddour Director | Sale | 1,249 | $314.99 | $393K |
| Mar 5, 2021 | Joann A. Reed Director | Sale | 1,600 | $263.31 | $421K |
| Feb 9, 2021 | Joann A. Reed Director | Sale | 1,614 | $282.51 | $456K |
| Feb 9, 2021 | Joann A. Reed Director | Sale | 1,407 | $282.30 | $397K |
| Feb 9, 2021 | Joann A. Reed Director | Sale | 1,738 | $282.36 | $491K |
| Dec 4, 2020 | Edward Conard Director | Sale | 1,322 | $236.59 | $313K |
| Nov 12, 2020 | Robert G. Carson SVP Corporate Development | Sale | 2,277 | $227.95 | $519K |
Board and executive changes
Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.
- Aug 21, 2026
(b) On August 17, 2026, Robert L. Carpio III notified Waters Corporation (the “Company”) of his decision to resign from his position as Senior Vice President, Waters Analytical Sciences Division to pursue other opportunities. Mr. Carpio relinquished his duties related to such position effective August 20, 2026.
Read the 8-K filing - Feb 9, 2026
Appointment of New Director In connection with the closing of the Transactions and in accordance with the terms of the Merger Agreement, the board of directors (the “Board”) of Waters increased the size of the Board from 10 to 11 members and appointed Claire M. Fraser, Ph.D. to the Board, effective February 9, 2026, to fill the vacancy so created. Dr. Fraser will serve as a director until Waters’ 2026 annual meeting of stockholders (the “2026 AGM”) or until her earlier resignation, death or removal. The Board has determined that Dr. Fraser meets the independence standards established under the New York Stock Exchange corporate governance listing standards. There are no related party transactions between Waters and Dr. Fraser that would require disclosure under Item 404(a) of Regulation S-K. Dr.
Read the 8-K filing - Nov 1, 2024
This is an amendment to Item 5.02 of the Current Report on Form 8-K that was filed by Waters Corporation (the “Company”) on August 14, 2024, which reported that on August 13, 2024, the Company’s Board of Directors (the “Board”) appointed Heather Knight to serve on the Company’s Board, effective as of August 14, 2024. On October 31, 2024, at a meeting of the Board, the Board appointed Heather Knight to the Nominating and Corporate Governance Committee, effective immediately. The information reported under
Read the 8-K filing - Aug 14, 2024
On August 13, 2024, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Heather Knight to the Board, effective August 14, 2024, to fill the vacancy so created. Ms. Knight will serve as a director until the Company’s 2025 annual meeting of stockholders (the “2025 AGM”) or until her earlier resignation, death, or removal. The Board has determined that Ms. Knight meets the independence standards established under the New York Stock Exchange corporate governance listing standards. Ms. Knight will receive the standard compensation paid by the Company to all of its non-employee directors and as described under “Director Compensation” in the Company’s Proxy Statement for its 2024 annual meeting of stockholders filed with the Securities and Exchange Commission on April 12, 2024.
Read the 8-K filing - Oct 24, 2023
(b) On October 18, 2023, Jonathan Pratt notified Waters Corporation (the “Company”) of his decision to resign from his position as Senior Vice President of the Waters Division, effective October 24, 2023.
Read the 8-K filing - Mar 28, 2023
(d) On March 27, 2023, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Richard Fearon to the Board, effective March 27, 2023, to fill the vacancy so created. Mr. Fearon will serve as a director until the Company’s 2023 annual meeting of stockholders (the “2023 AGM”) or until his earlier resignation, death, or removal. The Board has also appointed Mr. Fearon to its Audit Committee, effective March 27, 2023, and as of such time the Audit Committee will be comprised of Linda Baddour, Dan Brennan, and Richard Fearon. The Board has determined that Mr. Fearon meets the independence standards established under the New York Stock Exchange corporate governance listing standards. Mr.
Read the 8-K filing - Dec 14, 2022
(d) This is an amendment to Item 5.02 of the Current Report on Form 8-K that was filed by Waters Corporation (the “Company”) on November 23, 2022, which reported that on November 22, 2022, the Company’s Board of Directors (the “Board”) appointed Messrs. Dan Brennan and Mark Vergnano to serve on the Company’s Board, effective as of November 23, 2022. On December 13, 2022, at a meeting of the Board, the Board appointed Dan Brennan to the Audit Committee and Mark Vergnano to the Nominating and Corporate Governance Committee, effective immediately. The information reported under
Read the 8-K filing - Nov 23, 2022
(d) On November 22, 2022, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 7 to 9 members and appointed Dan Brennan and Mark P. Vergnano to the Board, effective November 23, 2022, to fill the vacancies so created. Messrs. Brennan and Vergnano will serve as directors until the Company’s 2023 annual meeting of stockholders or until their respective earlier resignation, death, or removal. The Board has not yet determined on which committees of the Board Messrs. Brennan and Vergnano will serve. The Board has determined that both Mr. Brennan and Mr. Vergnano meet the independence standards established under the New York Stock Exchange corporate governance listing standards. Messrs.
Read the 8-K filing - Aug 2, 2022
(b) On July 28, 2022, Thomas Salice notified the Company of his decision to retire from the Board of Directors (the “Board”) as of such date. Effective upon Mr. Salice’s retirement as a director, the size of the Board has been reduced from eight to seven directors. Waters previously communicated that Mr. Salice intended for this to be his final term as a director. Mr. Salice has provided thoughtful financial and strategic perspective during his tenure. Waters thanks Mr. Salice for his leadership and service to the Company and wishes him the best. The Board has an active and robust search underway to identify new directors consistent with its longstanding commitment to refreshment. This process has reinforced the Company’s confidence in identifying outstanding and qualified candidates to join the Waters Board.
Read the 8-K filing - Apr 1, 2022
(b) On March 30, 2022, John Ballbach resigned from the Board of Directors (the “Board”) of Waters Corporation, effective as of such date. Mr. Ballbach has provided insightful strategic, operational and relevant industry perspective during his tenure. The Company thanks him for his service. 1
Read the 8-K filing - Oct 6, 2021
(b) On October 1, 2021, Dr. Michael Berendt notified the Board of Directors (the “Board”) of Waters Corporation (the “Company”) of his decision to retire as director of the Company, including from any committees thereof, such retirement, effective October 5, 2021. (d) On October 5, 2021, the Board appointed John M. Ballbach to the Board, effective October 5, 2021, to fill the vacancy left by Dr. Berendt’s retirement. Mr. Ballbach will serve as a director until the Company’s 2022 annual meeting of stockholders or until his earlier resignation, death or removal. In connection with Mr. Ballbach’s appointment, the Board also appointed Mr. Ballbach to serve as a member of the Audit Committee. The Board has determined that Mr. Ballbach meets the independence standards established under the New York Stock Exchange corporate governance listing standards. Mr.
Read the 8-K filing - Jun 24, 2021
(d) On June 23, 2021, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Wei Jiang to the Board, effective July 14, 2021, to fill the vacancy so created. Mr. Jiang will serve as a director until the Company’s 2022 annual meeting of stockholders or until his earlier resignation, death or removal. The Board has not yet determined on which committees of the Board Mr. Jiang will serve. The Board has determined that Mr. Jiang meets the independence standards established under the New York Stock Exchange corporate governance listing standards. Mr.
Read the 8-K filing - Apr 21, 2021
(b), (c) and (e) On April 21, 2021, Waters Corporation (the “Company”) announced that Amol Chaubal had been hired to serve as the Company’s Senior Vice President and Chief Financial Officer, effective May 12, 2021. Michael Silveira, the Company’s interim Chief Financial Officer, will resume his position as Vice President Corporate Finance & Corporate Controller, effective May 12, 2021. Mr. Silveira will no longer serve as the Company’s principal financial officer and principal accounting officer of the Company, effective May 12, 2021. Mr. Chaubal, age 45, joins the Company from Quanterix Corporation, a life sciences company, where he served as Chief Financial Officer since April 2019. Before Quanterix, Mr. Chaubal served as CFO, Global Operations at Smith & Nephew, a global medical devices company, from October 2017 to April 2019.
Read the 8-K filing - Dec 15, 2020
(c) As previously reported by Waters Corporation (the “Company”) in a Current Report on Form 8-K filed with the Securities and Exchange Commission on December 3, 2020 (the “Initial Form 8-K”), the Company’s board of directors (the “Board”) appointed Michael Silveira to serve as the Company’s Chief Financial Officer on an interim basis, effective January 1, 2021. This amendment to the Initial Form 8-K is being filed to report that, on December 9, 2020, the compensation committee of the Board approved additional cash compensation for Mr. Silveira commencing January 1, 2021 and for so long as he continues to serve as interim Chief Financial Officer in the form of a cash stipend of $6,000 per Company pay period to compensate him for such role.
Read the 8-K filing - Dec 10, 2020
(d) On December 9, 2020, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Pearl S. Huang to the Board, effective January 1, 2021, to fill the vacancy so created. Dr. Huang will serve as a director until the Company’s 2021 annual meeting of stockholders or until her earlier resignation, death or removal. In connection with Dr. Huang’s appointment, the Board also appointed Dr. Huang to serve as the Chairperson of the Science and Technology Committee. The Company announced the appointment of Dr. Huang in its December 10, 2020 press release. The Board has determined that Dr. Huang meets the independence standards established under the New York Stock Exchange corporate governance listing standards. Dr.
Read the 8-K filing
Show 15 older changes
- Dec 3, 2020
(b) On November 27, 2020, Sherry L. Buck tendered her resignation from her position as Senior Vice President and Chief Financial Officer of Waters Corporation (the “Company”), effective December 31, 2020. (c) On December 1, 2020, Michael Silveira, 54, the Company’s Vice President Corporate Finance & Corporate Controller, was appointed by the Company’s board of directors to serve as the Company’s Chief Financial Officer on an interim basis, effective on January 1, 2021. Mr. Silveira will also serve as the Company’s principal financial officer and principal accounting officer. Mr. Silveira joined the Company in 2004 as Assistant Corporate Controller with duties that included accounting and external reporting. In 2013, Mr.
Read the 8-K filing - Aug 17, 2020
On August 17, 2020, Dr. Laurie H. Glimcher notified Waters Corporation (the “Company”) of her decision to resign from her position as a member of the Board of Directors (the “Board”) of the Company, including any committees thereof, effective immediately. Effective upon Dr. Glimcher’s resignation as a director, the size of the Board has been reduced from ten to nine directors.
Read the 8-K filing - Jul 15, 2020
On July 15, 2020, the Company announced that Dr. Udit Batra has been hired to serve as its President and Chief Executive Officer (“CEO”) and as a member of its Board of Directors, commencing on September 1, 2020. Previously, Dr. Batra, age 49, served as the Chief Executive Officer of the $7.7 billion Life Sciences business of publicly traded Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada. In connection with Dr. Batra’s hiring, on July 14, 2020, the Company entered into an offer letter (the “Employment Agreement”) with Dr. Batra. The Employment Agreement provides that, effective September 1, 2020, Dr. Batra will serve as the President and CEO of the Company and will be appointed as a member of its Board of Directors. Pursuant to the terms of the Employment Agreement, Dr.
Read the 8-K filing - Jun 17, 2020
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On June 17, 2020, Waters Corporation (the “ Company ”) announced the planned departure of Christopher J. O’Connell, President and Chief Executive Officer, effective as of the Company’s appointment of a successor. Mr. O’Connell will also resign from the Board of Directors of the Company at such time. Following his resignation as President and Chief Executive Officer, Mr. O’Connell will continue to be employed by the Company as a Senior Advisor until December 31, 2020. Separation Agreement Mr. O’Connell has entered into a Transition and Separation Agreement with the Company dated June 17, 2020 (the “Separation Agreement”). Consistent with Mr.
Read the 8-K filing - Apr 28, 2020
On April 28, 2020, the Company announced that, given the uncertain global business environment relating to the COVID-19 pandemic and the anticipated impact on its business, it has implemented a comprehensive program to reduce its cost base. As part of this program, the Company and each member of the Company’s Executive Committee have agreed to a temporary reduction in base salary for the 90-day period beginning on April 26, 2020. The Company’s Chief Executive Officer, Christopher J. O’Connell, has agreed to a 40% reduction in base salary. Each of the Company’s named executive officers, Sherry L. Buck, Keeley A. Aleman, Michael C. Harrington and Jonathan M. Pratt, has agreed to a 30% reduction in base salary.
Read the 8-K filing - Feb 19, 2020
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On February 17, 2020, Francis S. Kim, Senior Vice President, Global Operations, of Waters Corporation (the “ Company ”), informed the Company of his intention to voluntarily resign effective March 16, 2020.
Read the 8-K filing - Sep 6, 2018
(d) On September 1, 2018, the board of directors (the “Board”) of Waters Corporation (the “Company”) elected Linda Baddour, former Chief Financial Officer of PRA Health Sciences Inc., and Gary Hendrickson, former Chairman, President and Chief Executive Officer of Valspar Corporation, as directors of the Company. The Board has not yet determined on which committees of the Board Ms. Baddour and Mr. Hendrickson will serve. Ms. Baddour has served as Executive Vice President and Chief Financial Officer of PRA Health Sciences since 2007. Previously, she was the Chief Financial Officer at Pharmaceutical Product Development, Inc., where she also managed the company’s mergers & acquisitions and information technology strategies. Prior to being named Chief Financial Officer at Pharmaceutical Product Development, Inc., she was Treasurer and Chief Accounting Officer. Ms.
Read the 8-K filing - Oct 20, 2017
(b) On October 17, 2017, Douglas A. Berthiaume notified Waters Corporation (the “Company”) of his decision to resign as a Director and Chairman of the Board of the Company, effective December 31, 2017.
Read the 8-K filing - Jul 26, 2017
On July 21, 2017 Rohit Khanna entered into an agreement (the “Agreement”) with Waters Corporation (the “Company”) under which Mr. Khanna resigned from his position as Senior Vice President, Applied Technology as of July 21, 2017, and will continue to serve as Senior Vice President of the Company and as a member of its executive committee until his retirement on December 31, 2017, in each case subject to the terms of the Agreement. Mr. Khanna will remain entitled to receive his current base salary and to participate in the Company’s bonus plan and benefit plans during the term of the Agreement. Upon his termination of employment on December 31, 2017 (or upon an earlier termination of employment as provided in the Agreement), Mr.
Read the 8-K filing - Jun 22, 2017
(d) On June 22, 2017, the board of directors (the “Board”) of Waters Corporation (the “Company”) elected Dr. Flemming Ornskov, Chief Executive Officer of Shire plc, as a director of the Company. Dr. Ornskov has not yet been named to a committee of the Board. Since April 2013, Dr. Ornskov has served as the Chief Executive Officer, Chairman of the Executive Committee, and a member of the Board of Directors of Shire plc. From 2010 to 2012, Dr. Ornskov was Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer AG. Dr. Ornskov also held key executive leadership positions at Bausch & Lomb, Inc., Merck & Co., Inc. and Novartis AG. Dr. Ornskov received his Doctor of Medicine (MD) from the University of Copenhagen, his Master of Business Administration (MBA) from INSEAD, and his Master of Public Health (MPH) from Harvard University.
Read the 8-K filing - Mar 27, 2017
(e) On March 23, 2017, Waters Corporation (the “Company”) entered into Change of Control/Severance Agreements with its executive officers, including: Mark T. Beaudouin, Senior Vice President, General Counsel and Secretary; Eugene G. Cassis, Senior Vice President and Senior Advisor; Michael C. Harrington, Senior Vice President, Global Markets; Rohit Khanna, Senior Vice President, Applied Technology; Ian S. King, Senior Vice President, Instrument Technology; and Elizabeth B. Rae, Senior Vice President, Human Resources. This Change of Control/Severance Agreement will supersede the executive’s existing Change of Control/Severance Agreement with the Company. The following is a summary of the material changes to the Change of Control/Severance Agreements from the existing agreements.
Read the 8-K filing - Mar 13, 2017
(b) On March 7, 2017, Joshua Bekenstein notified Waters Corporation (the “Company”) of his decision to resign as a Director of the Company, effective immediately.
Read the 8-K filing - Dec 15, 2016
(e) On December 9, 2016, the Compensation Committee of the Board of Directors of Waters Corporation (the “Company”) approved the form of Performance Stock Unit Award Agreement (the “Form Award Agreement”) to be used for awards of performance stock units (“PSUs”) under the Waters Corporation 2012 Equity Incentive Plan. The Form Award Agreement is filed herewith as Exhibit 10.1 and is incorporated herein by reference. The description in this Form 8-K of the Form Award Agreement is qualified in its entirety by reference to the copy of the Form Award Agreement that is filed herewith as Exhibit 10.1. In a meeting held on December 9, 2016, the Compensation Committee of the Board of Directors approved the following awards of PSUs to certain of the Company’s executive officers: Executive/Title Target Number of PSUs Granted (# of shares) Christopher J.
Read the 8-K filing - Dec 8, 2016
On December 5, 2016, Eugene G. Cassis, Senior Vice President and Chief Financial Officer of Waters Corporation (the “Company”), communicated his intention to transition to a reduced workload and resign as the Company’s Chief Financial Officer effective January 9, 2017. Mr. Cassis will then continue to serve the Company in a senior advisory capacity. The Board of Directors of the Company has elected Sherry Buck, age 53, to serve as the Company’s Senior Vice President and Chief Financial Officer effective January 9, 2017. Previously, Ms. Buck served as the Vice President, Chief Financial Officer of Libbey Inc., Toledo, Ohio since 2012. Prior to that, she served as Vice President Finance/Chief Financial Officer, Global Product and Enterprise Cost Leadership, at Whirlpool Corporation, Benton Harbor, Michigan, since October 2010. In connection with Ms.
Read the 8-K filing - Jan 25, 2016
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing
Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021
Share price
Annual financials
From the company's 10-K XBRL data (SEC companyfacts).
| Fiscal year | Revenue | Net income | Margin | Diluted EPS | Total assets |
|---|---|---|---|---|---|
| FY2025 | $3.2B | $642.6M | 20.3% | $10.76 | $5.1B |
| FY2024 | $3.0B | $637.8M | 21.6% | $10.71 | $4.6B |
| FY2023 | $3.0B | $642.2M | 21.7% | $10.84 | $4.6B |
| FY2022 | $3.0B | $707.8M | 23.8% | $11.73 | $3.3B |
| FY2021 | $2.8B | $692.8M | 24.9% | $11.17 | $3.1B |
| FY2020 | $2.4B | $521.6M | 22.1% | $8.36 | $2.8B |
| FY2019 | $2.4B | $592.2M | 24.6% | $8.69 | $2.6B |
| FY2018 | $2.4B | $593.8M | 24.5% | $7.65 | $3.7B |
Former directors and officers (29)
People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.